<DOC>
	<DOCNO>NCT00095134</DOCNO>
	<brief_summary>The purpose trial evaluate efficacy safety risperidone versus placebo subject Major Depressive Disorder sub-optimal response antidepressant therapy .</brief_summary>
	<brief_title>Study Comparing Adjunctive Risperidone Versus Placebo Major Depressive Disorder That Is Not Responding Standard Therapy</brief_title>
	<detailed_description>Many patient suffer Major Depressive Disorder ( MDD ) benefit show partial benefit current psychotropic therapy . This clinical trial seek study efficacy safety adjunctive treatment risperidone patient MDD fail adequately respond standard antidepressant treatment prior trial prospectively respond adequate treatment standard antidepressant therapy ( SAD ) . Patients enter open label phase study already take commercially available SAD minimum 4 week , provide dose optimal , continue dose SAD throughout four-week open-label six-week double-blind phase trial . If dose four week prior enter study optimal ( per standard clinical practice ) , dose increase within optimal range continue dose entire open-label SAD double-blind phase . During double-blind phase , subject receive adjunctive dose risperidone placebo , daily , add stable dose SAD . The start dose risperidone placebo 0.25 mg first three day double-blind phase , increase 0.5 mg day 4 14 . On 15th day phase , dose increase target dose 1.0 mg/day . If response dose optimal day 29 , increase 2.0 mg/day maintain duration 6-week double-blind phase . This dose may reduce 1.0 mg/day , must maintain dose remainder study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Understand sign inform consent form Age 1865 Healthy basis Physical Exam Treatment single antidepressant 4 week prior study start willingness maintain stable dose antidepressant throughout study Current diagnosis Major Depressive Disorder Judgement clinician subject show suboptimal response antidepressant Presence serious medical illness ( e )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>